证券日报网讯 12月24日，华大基因（300676）在互动平台回答投资者提问时表示，华大基因的主营业 务为通过基因检测、质谱检测、生物信息分析等多组学大数据技术手段，为科研机构、企事业单位、医 疗机构、社会卫生组织等提供研究服务和精准医学检测综合解决方案，目前暂未涉及益生菌的生产制 造。 ...

格隆汇12月24日丨华大基因(300676.SZ)在互动平台表示，华大基因的主营业务为通过基因检测、质谱 检测、生物信息分析等多组学大数据技术手段，为科研机构、企事业单位、医疗机构、社会卫生组织等 提供研究服务和精准医学检测综合解决方案，目前暂未涉及益生菌的生产制造。 ...

格隆汇12月24日丨华大基因(300676.SZ)在互动平台表示，公司主营业务为通过基因检测、质谱检测、 生物信息分析等多组学大数据技术手段，为科研机构、企事业单位、医疗机构、社会卫生组织等提供研 究服务和精准医学检测综合解决方案。暂未参与脑机接口方面的研发。 ...

Group 1 - The stock price of BGI Genomics is reported at 50.52 yuan, down by 1.73 yuan from the previous trading day, with a trading volume of 5.87 billion yuan [1] - BGI Genomics operates in the medical device industry, primarily providing research and health management services through genomic testing, mass spectrometry, and bioinformatics analysis. In 2024, the revenue from the genomics application sector is expected to account for 99.36% of total revenue [1] - On August 13, the company announced that its second-largest shareholder, Shenghua Investment, plans to reduce its holdings by up to 6.2748 million shares, representing 1.50% of the total share capital, with a potential reduction scale of approximately 382 million yuan based on the closing price on the announcement date. Since 2018, this shareholder has cumulatively reduced its holdings by 3.245 billion yuan [1] Group 2 - The controlling shareholder, BGI Technology, has pledged 69.58% of its shares [1] - In the first quarter of 2025, the company's revenue decreased by 18.18% year-on-year, resulting in a net loss of 52.7 million yuan [1] - On August 14, the net outflow of main funds was 130.0624 million yuan, with a cumulative net outflow of 211.8627 million yuan over the past five days [2]